Procter & Gamble Hygiene and Health Care (500459) Q3 24/25 earnings summary

Executive summary

• Unaudited financial results for the quarter and six months ended December 31, 2024, were approved and released following a Board meeting on February 11, 2025.

• An interim dividend of ₹110 per equity share was declared, payable on or before March 7, 2025, with a record date of February 20, 2025.

• The financial year-end has been changed from June 30 to March 31, making FY 2024-25 a nine-month period.

Financial highlights

• Revenue from operations for Q2 FY25 was ₹124,625 lakhs, up from ₹113,273 lakhs in the previous quarter and ₹113,093 lakhs in Q2 FY24.

• Profit before tax for Q2 FY25 was ₹36,413 lakhs, compared to ₹28,537 lakhs in the previous quarter and ₹30,851 lakhs in Q2 FY24.

• Net profit for Q2 FY25 was ₹26,859 lakhs, up from ₹21,190 lakhs in the previous quarter and ₹22,890 lakhs in Q2 FY24.

• Basic and diluted EPS for Q2 FY25 stood at ₹82.74, compared to ₹65.28 in the previous quarter and ₹70.51 in Q2 FY24.

• For the six months ended December 31, 2024, revenue was ₹237,898 lakhs and net profit was ₹47,536 lakhs.

Outlook and guidance

• Interim dividend of ₹110 per share declared for FY 2024-25, reflecting confidence in ongoing performance.

• The company will report for a nine-month financial year ending March 31, 2025, due to a change in fiscal year-end.